Heudobler, Daniel and Rechenmacher, Michael and Lueke, Florian and Vogelhuber, Martin and Pukrop, Tobias and Herr, Wolfgang and Ghibelli, Lina and Gerner, Christopher and Reichle, Albrecht (2018) Peroxisome Proliferator-Activated Receptors (PPAR) Agonists as Master Modulators of Tumor Tissue. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 19 (11): 3540. ISSN 1422-0067
Full text not available from this repository. (Request a copy)Abstract
In most clinical trials, thiazolidinediones do not show any relevant anti-cancer activity when used as mono-therapy. Clinical inefficacy contrasts ambiguous pre-clinical data either favoring anti-tumor activity or tumor promotion. However, if thiazolidinediones are combined with additional regulatory active drugs, so-called master modulators' of tumors, i.e., transcriptional modulators, metronomic low-dose chemotherapy, epigenetically modifying agents, protein binding pro-anakoinotic drugs, such as COX-2 inhibitors, IMiDs, etc., the results indicate clinically relevant communicative reprogramming of tumor tissues, i.e., anakoinosis, meaning communication' in ancient Greek. The concerted activity of master modulators may multifaceted diversify palliative care or even induce continuous complete remission in refractory metastatic tumor disease and hematologic neoplasia by establishing novel communicative behavior of tumor tissue, the hosting organ, and organism. Re-modulation of gene expression, for example, the up-regulation of tumor suppressor genes, may recover differentiation, apoptosis competence, and leads to cancer controlin contrast to an immediate, poisoning' with maximal tolerable doses of targeted/cytotoxic therapies. The key for uncovering the therapeutic potential of Peroxisome proliferator-activated receptor (PPAR) agonists is selecting the appropriate combination of master modulators for inducing anakoinosis: Now, anakoinosis is trend setting by establishing a novel therapeutic pillar while overcoming classic obstacles of targeted therapies, such as therapy resistance and (molecular-)genetic tumor heterogeneity.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | C-REACTIVE-PROTEIN; PHASE-II TRIAL; GAMMA LIGAND TROGLITAZONE; CHRONIC MYELOID-LEUKEMIA; LOW-DOSE CHEMOTHERAPY; HUMAN BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; NUCLEAR RECEPTORS; METRONOMIC CYCLOPHOSPHAMIDE; TRANSCRIPTIONAL ACTIVATION; anakoinosis; communicative reprogramming; nuclear transcription factors; metronomic low-dose chemotherapy; glitazones; all-trans retinoic acid; COX-2 inhibitor; master modulators; undruggable targets; therapy pillar; peroxisome proliferator-activated receptors (PPARs); energy homeostasis; metabolic regulations; organ cross-talk; cancer and reprogramming of energy metabolism; systems biology |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Petra Gürster |
| Date Deposited: | 17 Jul 2020 09:03 |
| Last Modified: | 17 Jul 2020 09:03 |
| URI: | https://pred.uni-regensburg.de/id/eprint/13599 |
Actions (login required)
 |
View Item |
